

Stephen A. Williams

Major: Chemistry

University: Southern University of New Orleans

Faculty Mentor: Dr. Silvia Jurisson

Mentor Department: Chemistry

Funded by: NSF-REU/NIH Program in Radiochemistry

Reduction of rhenium^V oxo Schiff base complexes with triethylphosphine

Stephen A. Williams, Stephanie R. Lane, Nebiat Sisay and Silvia S. Jurisson

Pioneering techniques for therapeutic treatment of cancers involve targeting cancer sites with strong beta-emitting radionuclides, thereby destroying the cancer cells. This is achieved by coordinating the radioisotope to a very chemically stable environment and linking it to a specific biologically active targeting molecule, which interacts with particular cancer cells. Radioactive isotopes of rhenium possess characteristics of such a nuclide. The focus of our research is to investigate two possible pathways for the reaction of [ReOX(Schiff base)] with phosphine ligands, one a mono-substituted Re^V complex and one a di-substituted Re^{III} complex. The preferred Re^{III} complex is lower in oxidation state and more kinetically inert or stable relative to Re^V. For practical applications it is necessary to have an extremely stable *in vivo* radionuclide complex which can be conjugated to a suitable biological targeting agent.

The rigid sal₂phen ligand, where Sal₂phen is a tetradentate Schiff base ligand, was investigated to determine if the Re^{III} could be synthesized from the Re^V starting complex [Re^VOCl(Sal₂phen)]. [Re^VOCl(Sal₂phen)] was reacted with triethylphosphine (PET₃) in attempts to yield the Re^{III} complex *trans*-[Re^{III}(PET₃)₂(Sal₂phen)][X]. Previous work indicated that the strongly reducing and strongly nucleophilic PET₃ might yield the Re^V product from [Re^VOCl(Sal₂phen)]. The synthesized coordinated complex was reacted with an quaternary ammonium salt, ammonium hexafluorophosphate (NH₄PF₆), to induce crystallization of target compound [Re^{III}(PET₃)₂(Sal₂phen)][PF₆].

Preliminary ¹H-NMR, ³¹P-NMR, and infrared spectroscopy spectra indicate the formation of *cis*-[Re^VO(PPh₃)(Sal₂phen)][X]. FTIR shows the presence of the Rhenium oxo group; ³¹P-NMR and ¹H-NMR indicate the presence of Re^V and a 1:1 PET₃ : Sal₂phen complex. Single crystal x-ray diffraction, mass spectroscopy, and elemental analysis are additional methods of characterization.